Half-year report · HY
3645.TEDINET S100XFCO
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.3bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | ¥94m | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥48m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥165m | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥135m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥67m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥164m | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥59m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥91m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥68m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥17m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥110m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | ¥1m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥4.6bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥4.1bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥4.4bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.5bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥2.3bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥1.8bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.5bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.9bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥248m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥81m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥56m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥11m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥260m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥23m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥193m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥219m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥21m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥9.92 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.64 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.89 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 42.7% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.0% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.5% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-06-01 → 2025-11-30 | ¥90,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-06-01 → 2025-11-30 | ¥90,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-06-01 → 2025-11-30 | ¥90,000 |
| Cloud Integrationreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥221m |
| Cloud Integrationreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥221m |
| Cloud Integrationreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥48m |
| Mediaplatformreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥484m |
| Mediaplatformreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥484m |
| Mediaplatformreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥235m |
| Medical B To Breportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥79m |
| Medical B To Breportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥76m |
| Medical B To Breportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| Medical B To Breportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥11m |
| Medical Institution Management Supportreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥2.5bn |
| Medical Institution Management Supportreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥2.5bn |
| Medical Institution Management Supportreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥54m |
| —segment total | revenue | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| —segment total | revenue external | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| —segment total | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| —segment total | segment profit | 2025-06-01 → 2025-11-30 | ¥347m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2025-11-30 | ¥347m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-06-01 → 2024-11-30 | ¥908,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-06-01 → 2024-11-30 | ¥908,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-06-01 → 2024-11-30 | ¥908,000 |
| Cloud Integrationreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥219m |
| Cloud Integrationreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥219m |
| Cloud Integrationreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥41m |
| Mediaplatformreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥546m |
| Mediaplatformreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥546m |
| Mediaplatformreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥279m |
| Medical B To Breportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥87m |
| Medical B To Breportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥87m |
| Medical B To Breportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥11m |
| Medical Institution Management Supportreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥2.0bn |
| Medical Institution Management Supportreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥2.0bn |
| Medical Institution Management Supportreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥83m |
| Pre Symptomatic And Preventive Disease Platformreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥19m |
| Pre Symptomatic And Preventive Disease Platformreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥19m |
| Pre Symptomatic And Preventive Disease Platformreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥104m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥287m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥288m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 535
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら制限のない当社における標準となる株式 | |
| Description issued shares voting rights | InterimInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)株式会社メディカルネット | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)東京都渋谷区幡ヶ谷一丁目34番14号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Notes changes in accounting policies na semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and semi annual financial statements (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and semi annual financial statements (text) | InterimDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |